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Systemic bacterial infections are associated with high mortality. The access of bacteria or constituents
thereof to systemic circulation induces the massive release of immunomodulatory mediators, ultimately
causing tissue hypoperfusion and multiple-organ failure despite adequate antibiotic treatment. Lipid A, the
“endotoxic principle” of bacterial lipopolysaccharide (LPS), is one of the major bacterial immunostimuli. Here
we demonstrate the biological efficacy of rationally designed new synthetic antilipopolysaccharide peptides
(SALPs) based on the Limulus anti-LPS factor for systemic application. We show efficient inhibition of
LPS-induced cytokine release and protection from lethal septic shock in vivo, whereas cytotoxicity was not
observed under physiologically relevant conditions and concentrations. The molecular mechanism of LPS
neutralization was elucidated by biophysical techniques. The lipid A part of LPS is converted from its
“endotoxic conformation,” the cubic aggregate structure, into an inactive multilamellar structure, and the
binding affinity of the peptide to LPS exceeds those of known LPS-binding proteins, such as LPS-binding
protein (LBP). Our results thus delineate a novel therapeutic strategy for the clinical management of patients
with septic shock.
The life-threatening clinical consequences of sepsis and sep-
tic shock arise from recognition of microbial immunostimula-
tory molecules by the hosts’ professional immune cells and the
release of hemodynamically active mediators. The most potent
immunostimulatory constituents are part of the microbial cell
envelope, such as lipopolysaccharide (LPS) or lipoproteins.
They are released continuously due to cell growth and division
and massively liberated as a consequence of the attack of the
immune system. In the case of Gram-negative bacteria, the
most potent factor is LPS, which, therefore, is also called an
endotoxin. LPS concentrations in blood serum as low as 1
ng/ml are able to cause sepsis. Septic shock resulting from
bacterial infection remains a frequent cause of death, particu-
larly in intensive care units, with more than 200,000 people
dying each year in the United States alone. Death by septic
shock can happen despite appropriate broad-range antibiotic
treatment, which may kill bacteria but is not only incapable of
neutralizing immunostimulatory LPS but also may promote its
release into circulation (11).
The response of mammalian cells to LPS is initiated by its
interaction with serum proteins such as lipopolysaccharide-
binding protein (LBP) and specific receptors and/or binding
proteins of immune cells such as soluble CD14 (sCD14) and
membrane-bound CD14 (mCD14), which finally leads to cell
activation through the Toll-like receptor 4 (TLR4)–MD-2
pathway (31). The hydrophobic moiety of LPS, lipid A, an-
choring LPS to the bacterial outer membrane, constitutes the
“endotoxic principle” of LPS (24). Enterobacterial lipid A con-
sists of a diglucosamine backbone phosphorylated at positions
1 and 4, to which six acyl chains are linked at positions 2,3 and
2,3. The physicochemical properties of LPS suggest that cat-
ionic amphiphilic agents could effectively neutralize its lipid A
moiety. A number of studies have used natural proteins, pep-
tides, or modified variants thereof to neutralize LPS and, thus,
to protect it from endotoxin-mediated immunostimulation (1,
10), and in some cases, a significant protection from LPS-
induced lethality in vivo was observed (10, 19). However, these
approaches required very high peptide/LPS molar ratios, pre-
cluding their use in humans due to the intrinsic cytotoxicity of
the peptides at these concentrations.
We have designed a completely new class of peptides—
synthetic anti-LPS peptides (SALPs). SALPs were originally
based on the LPS-binding domain of the Limulus anti-LPS
factor (LALF) (2) but were substantially changed in length and
primary sequence for optimal binding to the lipid A portion of
LPS. Here, we report that these peptides are highly efficient in
neutralization of LPS and blockage of its immunopathological
consequences in vitro and in vivo. Our preclinical study reveals
that these SALPs combine excellent selectivity for LPS, with
high neutralizing activity in vitro and potent protection to sep-
tic shock using the murine model in vivo. We also demonstrate
very low cytotoxicity under physiological conditions, making
these SALPs promising candidates for their application as
therapeutic agents for the prevention and treatment of sep-
tic shock. The molecular interaction mechanism between
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SALPs and LPS was studied using various biophysical ap-
proaches.
MATERIALS AND METHODS
Lipids. Lipopolysaccharides from the rough mutants Re and Ra from Salmo-
nella enterica serovar Minnesota (R595 and R60, respectively) were extracted by
the phenol-chloroform/petrol ether method (13) from bacteria grown at 37°C,
purified, and lyophilized. Results from all the standard assays performed on the
purified LPS (analysis of the amount of glucosamine, total and organic phos-
phate, and the distribution of the fatty acid residues) were in good agreement
with the chemical properties expected for the LPS chemotypes, whose molecular
structures have already been solved (23). S-lipopolysaccharides of Escherichia
coli ATCC 35218 and Pseudomonas aeruginosa PAO1 for mouse testing were
obtained from the aqueous phase of a water-phenol extract and purified by
treatment with chaotropic agents and detergents, according to published proce-
dures (14, 17).
Preparation of endotoxin aggregates. LPS was solubilized in the appropriate
buffer (lipid concentration of 1 to 10 mM, depending on the applied technique),
extensively vortexed, sonicated for 30 min in a water bath, and subjected to
several temperature cycles between 20 and 60°C. Finally, the lipid suspension was
incubated at 4°C for at least 12 h before use.
Peptide synthesis. The peptides were synthesized with an amidated C terminus
by the solid-phase peptide synthesis technique in an automatic peptide synthe-
sizer (model 433A; Applied Biosystems) on Fmoc-Rink amide resin, according to
the 0.1-mmol FastMoc synthesis protocol of the manufacturer, including the
removal of the N-terminal Fmoc group. The peptidyl resin was deprotected and
cleaved with a mixture of 90% trifluoroacetic acid (TFA), 5% anisole, 2%
thioanisole, and 3% dithiothreitol for 90 min at room temperature. After cleav-
age, the suspension was filtered through a syringe filter into ice-cold diethyl
ether. The precipitated peptides were separated by centrifugation and repeatedly
washed with cold ether. The final purification was done by reverse-phase high-
pressure liquid chromatography (RP-HPLC). Purity levels of up to 98% were
achieved by using an Aqua C18 column (Phenomenex) in combination with
dedicated gradients of acetonitrile in 0.1% TFA, checked by matrix-assisted laser
desorption ionization–time of flight (MALDI-TOF) mass spectroscopy and RP-
HPLC at 214 nm. The sequences of the peptides were submitted in an interna-
tional patent, which was published in October 2009 by the European Patent
Office (patent 2108 372 A1).
Isothermal titration calorimetry (ITC). Microcalorimetric experiments of
peptide binding to LPS were performed on a MSC isothermal titration calorim-
eter (MicroCal Inc., Northampton, MA) at 40°C. Briefly, after thorough degas-
sing of the samples, peptide (1 to 4 mM in 20 mM HEPES, pH 7.0) was titrated
to an LPS suspension (0.05 mM in 20 mM HEPES, pH 7.0). The enthalpy change
during each injection was measured by the instrument, and the area underneath
each injection peak was integrated (Origin; MicroCal) and plotted against the
molar ratio of the concentrations of peptide to LPS. Titration of the pure peptide
into HEPES buffer resulted in a negligible endothermic reaction due to dilution,
which was subtracted from the plotted curves. The experiments were done at
least twice.
Small-angle X-ray scattering (SAXS) with synchrotron radiation. X-ray scat-
tering measurements of mixtures of lipid A with Pep19-2.5 were performed at the
European Molecular Biology Laboratory (EMBL) outstation at the Hamburg
synchrotron radiation facility HASYLAB using the double-focusing monochro-
mator-mirror camera X33 (16). Diffraction patterns in the range of the scattering
vector 0.001  s  0.08 Å1 (where s is 2 sin /, 2 is the scattering angle, and
 is the wavelength, which was 1.5 Å) were recorded at 20, 40, and 60°C, with
exposure times of 1 min using an image plate detector with online readout
(mar345; Marresearch, Norderstedt, Germany) (26). The s axis was calibrated
with Ag-behenate, which has a periodicity of 58.4 Å. The diffraction patterns
were evaluated as described previously (6), assigning the spacing ratios of the
main scattering maxima to defined three-dimensional structures. The lamellar
and cubic structures are most relevant here and are characterized by the follow-
ing features. (i) Lamellar structures: the reflections are grouped in equidistant
ratios, i.e., 1, 1/2, 1/3, 1/4, etc. of the lamellar repeat distance dl. (ii) Cubic
structures: the different space groups of these nonlamellar three-dimensional
structures differ in the ratio of their spacings. The relationship between recip-
rocal spacing shkl  1/dhkl and lattice constant a is shkl  [(h2  k2  l2)/a]1/2
(hkl  Miller indices of the corresponding set of plane).
Stimulation of human MNC by LPS. Mononuclear cells (MNC) were isolated
from heparinized blood samples obtained from healthy donors as described
previously (15). The cells were resuspended in medium (RPMI 1640), and their
number was equilibrated at 5  106 cells/ml. For stimulation, 200 	l MNC (1 
106 cells) was transferred into each well of a 96-well culture plate. LPS Ra (from
S. Minnesota strain R60) and the LPS/peptide ratio mixtures were preincubated
for 30 min at 37°C and added to the cultures at 20 	l per well. The cultures were
incubated for 4 h at 37°C with 5% CO2. Supernatants were collected after
centrifugation of the culture plates for 10 min at 400  g and stored at 20°C
until immunological determination of tumor necrosis factor alpha (TNF-
),
carried out with a sandwich enzyme-linked immunosorbent assay (ELISA) using
a monoclonal antibody against TNF (clone 6b; Intex AG, Switzerland) and
described previously in detail (15).
Cytotoxicity assays and hemolysis. Cytotoxicity was assayed by using the chip-
based Bionas system with four different cell types. These include human hepa-
toma cells (HepG2), human colon adenocarcinoma cells (LS-174T), human
acute lymphocytic leukemic cells (Jurkat), and human peripheral blood mono-
nuclear cells (hPBMC), provided by Cell Line Services (Piscataway, NJ) and
ProBioGen (Berlin, Germany). The cells were seeded on chips, with a density of
200,000 cells/chip for HepG2 and LS-174T, 300,000 cells/chip for Jurkat, and 2
million cells/chip for PBMC.
Red blood cells (RBCs) were obtained from citrated human blood by centrif-
ugation (1,500  g, 10 min), washed three times with isotonic 20 mM phosphate-
NaCl buffer (pH 7.4), and suspended in the same buffer at a concentration
equivalent to 5% of the normal hematocrit. Forty-microliter aliquots of this RBC
suspension were added to 0.96 ml of peptide dilutions prepared in the same
isotonic phosphate solution, incubated at 37°C for 30 min, and centrifuged
(1,500  g, 10 min). The supernatants were analyzed spectrophotometrically
(with absorbance at 543 nm) for hemoglobin, and results were expressed as the
percentage released with respect to sonicated controls (100% release) or controls
processed without peptides (0% release) (21).
Assays for antibacterial activities. The antibacterial activity of the peptides
was determined by microdilution susceptibility assays performed in standard
Mueller-Hinton (MH) broth. Susceptibility testing was performed following the
recommendations of the Clinical and Laboratory Standards Institute (CLSI,
formerly NCCLS) (20). Briefly, serial 2-fold dilutions of the peptides were made
in MH broth and dispensed into 96-well U-bottom polystyrene microtiter plates.
Bacterial cells grown for 18 to 20 h on agar plates were suspended in saline, and
the turbidity was adjusted to an optical density at 600 nm (OD600) of 0.04 (1 
107 CFU/ml, approximately). A 100-fold dilution of this suspension prepared in
MH broth was mixed 1:1 with 100 	l of each of the corresponding peptide
dilutions. Plates were incubated at 37°C without shaking for 18 to 20 h, and the
MIC was determined visually.
Animal model of endotoxicity. As a compound for eliciting endotoxic shock,
LPS from Pseudomonas aeruginosa PA01 or from S. Minnesota strain R60 was
used.
Female C57/BL6 mice weighing 14 to 16 g (6 weeks old) were purchased from
Harlan Spain (Harlan Interfauna Iberica S.A., Barcelona, Spain) and randomly
distributed in experimental groups (n  8). Endotoxic shock was induced in the
animals by coinoculation of LPS and galactosamine by following the method of
Galanos et al. (12). Specifically, each animal received an intraperitoneal injection
containing a mixture of 25 ng of LPS from S. Minnesota R60 (or 150 ng when
using P. aeruginosa LPS) and 18 mg of galactosamine resuspended in 200 	l of
endotoxin-free saline.
Immediately after LPS administration, animals were intraperitoneally inocu-
lated with 12.5 or 1.25 	g (150 	g in the case of animals receiving P. aeruginosa
LPS) of the test peptide resuspended in 150 	l of pyrogen-free saline. To
facilitate the therapeutic action of the peptide, mice so treated were gently
massaged at the site of inoculation for a few seconds. Animal mortality was
monitored at 6 h and 24 h postinoculation and at daily intervals for 7 days.
In each independent experiment, a group of animals received 150 	l of pyro-
gen-free saline containing 12.5 	g of polymyxin B (PMB), a lipopeptide with
well-known antiendotoxic properties, whereas another group was left untreated.
The results of animal mortality at all experimental time points were globally
analyzed using Kaplan-Meier survival analysis (SPSS 15.0). When the survival
plots were parallel, data were compared by the log rank test, whereas for those
plots that intersected, the Breslow-Gehan-Wilcoxon test was applied. P values
were always obtained by comparing data from the same experiment (mortality in
treated versus untreated groups).
All the animal protocols used in this study were approved by the University of
Navarra Animal Research Committee (protocol 035/05).
RESULTS
Design of the SALP. The sequences of the Pep19 series
based on the Limulus anti-LPS factor, presented in Fig. 1A,
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were designed according to the following physicochemical cri-
teria. (i) The compounds require amphiphilic characters, i.e.,
they must contain sufficiently high numbers of polar and pos-
itively charged (basic) amino acids and corresponding hydro-
phobic residues. (ii) The number of basic (positively charged)
amino acids must be sufficiently high to bind to the negatively
charged moieties of the LPS backbone. For this, 7 or 8 arginine
(R) or lysine (K) residues were selected. The hydrophilic cat-
ionic part of the peptides was localized mainly near the N-
terminal residue, and the hydrophobic moiety was localized
mainly near the C-terminal end. The number of the hydropho-
bic residues, consisting essentially of tryptophan (W) and phe-
nylalanine (F), was 6 or 7. (iii) The length of the peptide should
be optimized to account for the length and character of the
lipid A moiety in such a way that the hydrophobic moiety of the
peptide readily intercalates into the hydrocarbon chains of
lipid A and the cationic moiety intercalates into the backbone-
adjacent oligosaccharide moiety of LPS. A medium length of
19 amino acids was assumed to represent an optimum, but a
maximum number of 23 amino acids was allowed. (iv) On the
basis of the best sequences, as judged by their ability to inhibit
cytokine production in human mononuclear cells (see below),
new peptide variants were synthesized. To this end, the se-
quence of compound Pep19-2 was used as a template, giving
rise to further peptides Pep19-2.2 to Pep19-2.5 (Fig. 1B).
Antibacterial activity. The antibacterial activity of the pep-
tides was assessed on strains of various clinically relevant bac-
teria (Table 1). The data clearly show extreme differences in
their MICs depending sensitively on the amino acid sequences.
The SALPs showed activity not only against Gram-negative
bacteria but also against Gram-positive bacteria. The compar-
ison shows that the GC motif at the N-terminal end and the
CG motif at the C-terminal end seem to be rather disadvan-
tageous, since compounds lacking the glycine moieties were
more active. Furthermore, peptides partially lacking that mo-
tif, such as Pep19-8, had increased potency against 2 methicil-
lin-resistant Staphylococcus aureus (MRSA) strains, with MIC
values around 8 	g/ml.
Inhibition of cytokine production in human mononuclear
cells. The LPS-induced production of tumor necrosis factor
alpha (TNF-
) by human mononuclear cells at three LPS con-
centrations (100, 10, and 1 ng/ml) and its inhibition by some
selected peptides (Pep19-2 and Pep19-8) at different LPS/pep-
tide weight ratios are plotted in Fig. 2A. Both peptides inhibit
the LPS-induced TNF-
 secretion to different degrees, show-
ing for Pep19-2 the highest efficacy by far at a Pep19-2/LPS
concentration ratio ([Pep19-2]/[LPS] ratio) of 100:1 weight
percent (corresponding to a molar ratio of 65:1). Similar re-
sults were found for Pep19-1 (data not shown). In contrast to
these compounds, Pep19-8 was much less active in the inhibi-
FIG. 1. Amino acid sequence of Pep19-derived peptides. (A) Se-
quences of the basic peptides Pep19-1 to Pep19-12 and their molecular
weights (MW). (B) Sequences of the Pep19-2 series. Amino acids: G,
glycine; C, cysteine; Q, glutamine; Y, tyrosine; R, arginine; K, lysine; F,
phenylalanine; W, tryptophan; L, leucine. The colors illustrate the
main physicochemical characteristics, as follows: green, polar; yellow,
hydrophobic; blue, basic (positively charged).
TABLE 1. MICs of peptides on indicated bacterial strains
Peptide
MIC (	g/ml)a
Bordetella
bronchiseptica
CUN 11844-99
P. aeruginosa
CUN 4158-02
P. aeruginosa
ATCC 27853
E. coli
ATCC 25922
S. aureus
ATCC 25923
MRSA
ATCC 43300
MRSA CUN
3792-99
Stenotrophomonas
maltophilia CUN
3998-00
Acinetobacter
baumannii
ATCC 19606
Pep19-1 4 256 256 64 32 64 1,024 512 64
Pep19-2 32 256 128 128 128 128 1,024 512 64
Pep19-4 4 16 16 16 16 16 16 32 16
Pep19-5 4 32 16 16 16 16 16 64 16
Pep19-6 16 256 256 1,024 1,024 64 32 1,024 64
Pep19-7 8 32 8 1,024 1,024 16 16 64 16
Pep19-8 128 32 16 16 8 8 8 32 16
Pep19-10 16 ND ND 64 32 ND ND ND ND
Pep19-11 32 128 128 128 64 32 64 64 64
Pep19-12 32 128 128 64 64 32 64 64 64
Pep19-2.2 64 128 64 64 64 32 64 128 64
a CUN, Clinica Universidad de Navarra (University Hospital of Navarra); MRSA, methicillin-resistant Staphylococcus aureus; ND, not done.
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tion of the LPS response (Fig. 2A), and a similar observation
was made for Pep19-5 (data not shown).
On the basis of these and other results on the inhibition of
the cytokine production, peptides containing variations of the
amino acid sequences were designed using Pep19-2, in partic-
ular, as a template, as shown in Fig. 1B. Data from the inhi-
bition assay are presented in Fig. 2B, showing the extreme
activity of Pep19-2.5 to inhibit the production of TNF-
 in-
duced by LPS at all investigated concentrations. Already at a
[Pep19-2.5]/[LPS] ratio of 3:1 weight (corresponding to a mo-
lar ratio of 1.9:1), there is nearly complete inhibition. This was
similarly true for Pep19-2.2 (data not shown). Comparative
measurements with polymyxin B (PMB), the gold standard of
antimicrobial peptides, showed that PMB causes some inhibi-
tion of the cytokine secretion at a [PMB]/[LPS] ratio of 10:1
weight (corresponding to a molar ratio of 3:1) but no inhibition
at lower peptide concentrations. This means that the best pep-
tides of the Pep19 series significantly outperform the LPS-
neutralizing activity of the gold standard.
A variant of Pep19-2.5, with its same amino acid composi-
tion but in a completely random sequence, called Pep19-2.5KO
was shown to still exert some inhibition but considerably lower
than that of the parent peptide (Fig. 2A).
Animal model of endotoxicity. To investigate whether the in
vitro data could be extended to an in vivo model of endotox-
icity, we evaluated the ability of various peptides to protect
mice against a lethal septic shock induced by the intraperito-
neal injection of LPS. Initially, Pseudomonas aeruginosa LPS
was used, harboring an endotoxic activity that is known to be
lower than that of Salmonella (see Materials and Methods). As
shown in Fig. 3A, the in vivo results, performed at a [peptide]/
[LPS] ratio of 1,000:1 weight (corresponding to a molar ratio of
approximately 600:1) were in good agreement with the in vitro
data, since the peptides with less inhibitory activity (Pep19-5
and Pep19-8) did not confer protection against LPS-induced
shock, whereas highly active compounds such as Pep19-2,
Pep19-12, and Pep19-2.2 protected the animals as efficiently as
polymyxin B.
In addition, the ability of the peptides to neutralize LPS of
enhanced endotoxicity was examined. Pep19-2.2 and Pep19-2.5
were selected, and the experimental setting was repeated using
LPS from S. enterica serovar Minnesota R60. As shown in Fig.
3B, administration of Pep19-2.5 conferred a significant level of
protection, similar to that of polymyxin B, whereas Pep19-2.2
was slightly less protective. Interestingly, animals receiving
Pep19-2.5 at doses 1 order of magnitude lower (2.5 	g, i.e., a
ratio of 1:50 weight percent, with respect to LPS) than the
previous one were fully protected during the first 48 h after
inoculation, although the therapeutic effect decreased slightly
at later time points
Cytotoxicity and hemolysis. To test possible side effects of
the peptides in physiologically relevant cells, several parame-
ters, including respiration rate, acidification, and impedance,
were monitored kinetically in a chip-based system (Bionas) at
concentrations of 0.01, 0.1, 1, 10, and 100 	g/ml. In Fig. 4A,
data for the respiration rates are shown for Jurkat cells, which
clearly give evidence that no damaging effect can be observed
at concentrations of up to 10 	g/ml. At 100 	g/ml Pep19-2.5,
FIG. 2. Inhibitory effect on LPS-induced cytokine release. LPS R60-induced secretion of TNF-
 by human mononuclear cells and the inhibitory
effect in the presence of the peptides Pep19-2 and Pep19-8 (A) and Pep19-2.5 and Pep19-2.5KO (Pep19-2.5 control) (B). The peptides were added
at the indicated weight ratios of the concentrations of LPS to peptide.
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however, the cells are irreversibly damaged. These observa-
tions were found to be true for all 4 different cellular systems,
namely, human hepatoma cells (HepG2), human colon adeno-
carcinoma cells (LS-174T), human acute lymphocytic leukamic
cells (Jurkat), and human peripheral blood mononuclear cells
(hPBMC). Similar results were also found for HeLa and
HaCaT cells using conventional test systems such as the 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) test (data not shown).
Using the red blood cell hemolysis assay for selected pep-
tides, no essential damage was observed at peptide concentra-
tions of up to 25 	g/ml (ca. 10 	M) (Fig. 4B).
Binding experiments. To understand the mechanisms of
binding, high-sensitivity isothermal titration calorimetry (ITC)
was applied by repeated titration of the peptide solution into
the LPS dispersion. The experiments show a strong exothermic
reaction due to Coulomb attraction between Pep19-2.5 and
LPS R60 (peaks downward), which runs into saturation already
at a [Pep19-2.5]/[LPS] ratio of 0.3 (Fig. 5). This means that
already 3 molecules of the peptide, corresponding to 24 posi-
tive charges, are sufficient to neutralize 10 LPS molecules (40
negative charges). Due to the amphiphilic character of the
peptide, saturation takes place before charge compensation.
Supramolecular aggregate structure by SAXS. It is known
that the bioactive aggregate structure of LPS or lipid A is cubic
(7). The influence of Pep19-2.5 on the aggregation properties
of lipid A was tested, because the scattering patterns of this
endotoxin species with its short sugar chain provide the best
resolution. In Fig. 6, the data are shown for pure lipid A (panel
A) and in the presence of a small amount of Pep19-2.5 (panel
B; [lipid A]/[Pep19-2.5] molar ratio of 7:1). Lipid A alone
expresses a complex spectrum with cubic symmetry, because
the reflections at 8.18, 5.29, and 4.06 nm obey the relations
aQ/2, aQ/5, and aQ/8, respectively, with a cubic period-
icity of aQ equaling 11.6  0.2 nm. In the presence of the
peptide, there is a complete conversion of the spectrum with
the appearance of one strong peak at 5.07 nm, corresponding
to the lamellar repeat characteristic of lipid A with multila-
mellar structure (7).
DISCUSSION
We have designed and synthesized cationic amphiphilic pep-
tides (synthetic antilipopolysaccharide peptides [SALPs])
which are able to neutralize bacterial endotoxins effectively in
an in vitro system—human mononuclear cells—as well as in
vivo in a murine animal model of endotoxicity. The best pep-
tides inhibit the production of TNF-
 in human mononuclear
cells already at a slightly excess weight percent or molar ratio
of the concentrations of peptide to LPS (Fig. 2A and B),
making them suitable candidates for antiseptic agents. This
was clearly demonstrated by employing the animal model of
Gram-negative sepsis, exhibiting considerable protection
against endotoxic shock (Fig. 3) even at a relatively low peptide
dose. Regarding the latter result, one has to take into account
that in the therapeutic situation, the peptide would be admin-
istered several times and not only once.
At the same time, neither hemolytic nor cytotoxic effects in
human hepatoma cells, human colon adenocarcinoma cells,
human acute lymphocytic leukamic cells (Fig. 4A), and human
peripheral blood mononuclear cells (hPBMC) or in human red
blood cells (Fig. 4B) was observed for doses of up to 10 	g/ml.
For an assessment of these data in relation to the situation
found in human septic patients with endotoxemia, it has to be
considered that under these conditions, blood serum levels of
1 ng/ml of LPS are observed (5). Both the in vitro and in vivo
test systems indicate that an excess [peptide]/[LPS] ratio of
100:1 weight percent is enough to inactivate LPS effectively.
This corresponds to a patient dose of 100 ng/ml, which is far
below any cytotoxically relevant concentration. According to
the cytotoxicity data, even a 10-fold-higher dose should not be
a problem, making these peptides potentially suitable candi-
dates for use with critical care unit patients. It is known that
severe sepsis or septic shock may arise from infections due to
Gram-negative bacteria in approximately 50% of all septic
patients (30). Therapy with conventional antibiotics may even
worsen this outcome, since many antimicrobial agents kill bac-
teria with subsequent release of LPS but do not inactivate LPS
(11). Thus, a possible therapeutic strategy would be the use of
FIG. 3. Protective effect in an in vivo endotoxin exposure model.
(A) Protection against lethal septic shock caused by injection of
Pseudomonas aeruginosa LPS. On day 0, a group of C57BL/6 mice (n
8) was inoculated intraperitoneally with a mixture of 18 mg galac-
tosamine and 150 ng LPS isolated from Pseudomonas aeruginosa
PAO1. Immediately afterward, animals received 150 	g of the test
peptide or 150 	g of polymyxin B at a different site of the peritoneum.
Animal mortality was monitored at daily intervals for 7 days. Statistical
differences were analyzed by the Kaplan-Meier survival test (***, P 
0.001; **, P  0.01). (B) S. Minnesota LPS. On day 0, a group of
C57BL/6 mice (n  8) was inoculated intraperitoneally with a mixture
of 18 mg galactosamine and 25 ng LPS from S. Minnesota R60. Im-
mediately afterward, animals received either 12.5 	g or 1.25 	g (1:500
and 1:50 weight ratios, with respect to LPS) of the test peptide or
polymyxin B at a different site of the peritoneum. Animal mortality was
monitored at daily intervals for 7 days. Statistical differences were
analyzed by the Kaplan-Meier survival test (***, P  0.001; **, P 
0.01).
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the peptides presented here, since these have nonnegligible
antibacterial activity levels (examples given in Table 1). In case
the antimicrobial action of these compounds was not sufficient
for clinical purposes, a therapeutic approach should involve
the combination of peptides and antibiotics.
In Table 1 and Fig. 2A, in particular for Pep19-2 and
Pep19-8, it becomes clear that the presented peptides differ in
their ability to neutralize LPS in isolated forms and as constit-
uents of Gram-negative bacteria. Pep19-2 is highly active
against free LPS but has very low activity against bacteria,
whereas the situation for Pep19-8 is the opposite. Therefore,
the specific arrangement of the amino acids plays a decisive
role, since both peptides have 8 cationic amino acids (R and L)
and 7 hydrophobic amino acids (F and W) at similar chain
positions. For strong anti-LPS activity, apparently the cysteine
FIG. 4. Characterization of peptide-associated cytotoxicity. (A) Respiration rates of Jurkat cells over 32 h at different concentrations of peptide
Pep19-2.5 in a chip-based cellular system. The first and last 5 h (gray regions) correspond to the lag and regeneration phases, respectively. (B) Red
blood cell hemolysis of selected peptides compared to that of melittin from bee venom (synthetic).
FIG. 5. Enthalpy of the peptide-LPS binding. Isothermal calori-
metric titration of a 1 mM Pep19-2.5 solution into a 0.05 mM LPS Ra
dispersion (from S. Minnesota R60). Every 5 min, 5 	l of the peptide
was titrated to the LPS dispersion, and the heat reaction was recorded.
A downward peak corresponds to an exothermic reaction, and an
upward peak corresponds to an endothermic reaction.
FIG. 6. Effect of Pep19-2.5 on the supramolecular lipid A aggre-
gate structure. Synchrotron radiation small-angle X-ray scattering pat-
terns of lipid A (top) and the [lipid A]/[Pep19-2.5] ratio of 7:1 M/M
(bottom). The logarithm of the scattering intensity is plotted versus the
scattering vector s (s  1/d, with d being the spacings of the reflec-
tions).
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in position 2 at the N-terminal end is essential, whereas this
residue is irrelevant for high antimicrobial activity of all pep-
tides (Pep19-4, -5, and -8) (Table 1). The selectivity of the
peptides to inactivate LPS could be due to the distinct geom-
etry of LPS, either in free form within a cubic aggregate struc-
ture (8) or as a constituent of the outer membrane leaflet. For
these different conformations, the structural prerequisites of
the peptides to neutralize LPS differ.
Differences between antimicrobial and anti-LPS activities
have also been described for peptides with K6L9 sequences
(28). Those authors emphasize that peptides with high endo-
toxin neutralizing activity levels are able to disaggregate the
LPS multimers, deduced using fluorescence dequenching and
electron microscopy (EM) with negative staining (27). In pre-
vious work on various peptides derived from the Limulus anti-
LPS factor (2), human granulysin-derived peptides (9), human
lactoferricin (4), and porcine NK2 (3), however, we found that
LPS neutralization is accompanied with a high increase in
endotoxin aggregation, leading to multilamellar structures
(Fig. 6), as also shown by freeze-fracture EM (2). Freeze-
fracture EM is more adequate than EM with negative staining,
with the latter changing the morphology of LPS due to the
change in water content, as demonstrated by Risco and co-
workers (25). Also, differences in the LPS preparation used
(Rosenfeld et al. used the LPS S form from E. coli O111:B4
[29]) cannot account for distinct aggregation properties, since
the peptides investigated here are equally efficient at inhibiting
the cytokine production induced by LPS from several rough
and smooth bacterial strains (LPS Re, LPS Rc, and LPS Ra, all
from S. enterica serovar Minnesota; LPS S form from Salmo-
nella abortusequi; LPS S form from E. coli 08:K27; and LPS
from Chromobacterium violaceum) (data not shown).
The decrease in LPS bioactivity with the increased size of
LPS aggregates can be explained by the fact that the binding
sites for mammalian proteins such as LBP, CD14, and others
are hidden in multilamellar aggregates rather than in cubic
aggregates. The change of LPS structure into a multilamellar
structure induced by the peptides found here (Fig. 6), which
has been shown to be connected with large increases in aggre-
gate sizes (2), is a necessary prerequisite for LPS inactivation.
In particular, the conversion of the lipid A aggregate into a
multilamellar arrangement already at a [lipid A]/[Pep19-2.5]
molar ratio of 7:1 shows that the degree of multilamellarization
can be correlated directly with the inhibition property in the
biological system. SAXS data with less-efficient peptides show
that the lipid A aggregate structures are multilamellarized only
at a much higher peptide concentration (data not shown).
A second factor is the high binding affinity of LPS to SALPs,
which must be higher than that of the LBP-LPS binding. In Fig.
5, it becomes clear that there is an extremely strong Coulomb
interaction between the positive charges of the peptide and the
negative charges of LPS connected with an incorporation of
the peptides into the LPS bilayer, with a saturation taking
place already at a [Pep19-2.5]/[LPS] ratio of 3:10 M/M.
In recent years, LPS-neutralizing antimicrobial peptides
have been in the focus of sepsis research (18–22, 28). In most
cases, however, the applied excess concentration ratio of pep-
tide to LPS, necessary for sufficiently high LPS inactivation,
was in the range of 1,000, or even higher, thus being insuffi-
ciently selective for LPS with respect to cytotoxic effects
against physiological mammalian cells.
The presented data are clearly indicative of the potential
ability of the peptides to act as antiseptic therapeutics. Further
experiments are in progress using a mouse model of sepsis
caused by bacterial infection, i.e., one based on inoculation of
Gram-negative bacterial cells rather than isolated LPS and
testing the action of the peptides in the absence and presence
of conventional antibiotics. Preliminary results show a signifi-
cant increase of survival only when peptide Pep19-2.5 is ad-
ministered in combination with an antibiotic (amikacin) (our
unpublished data). Delayed addition of the peptide after LPS
administration is also in the focus of our interest. Initial testing
with the same model of endotoxemia used in the present report
still shows a considerable increase in mouse survival when the
peptide Pep19-2.5 was added intraperitoneally after 0.5 to 2 h
of the LPS challenge. Furthermore, use of other animal models
of sepsis such as cecal ligation and puncture is presently on-
going and give evidence that Pep19-2.5 alone is able to signif-
icantly increase mouse survival (our unpublished data). These
data will be the focus of a follow-up study.
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